Literature DB >> 3286512

Pharmacokinetics of ciprofloxacin.

T Bergan1, A Dalhoff, R Rohwedder.   

Abstract

The fluorination of piperazinyl substituted quinolones has led to an interesting development of a series of new broad spectrum antibacterial agents that may be administered orally as well as parenterally and are well tolerated. Norfloxacin was an early compound, later followed by ciprofloxacin, enoxacin, ofloxacin and pefloxacin. In this overview the emphasis will be on the most extensively studied compound including comparisons, where data are available, with norfloxacin and ofloxacin. Enoxacin and pefloxacin will be omitted due to their pattern of side effects, which at present curtail their therapeutic use. More recent substances such as fleroxacin and defloxacin have not been sufficiently investigated to be considered in this context.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286512     DOI: 10.1007/bf01650500

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  40 in total

1.  Reduced enteral absorption of ciprofloxacin in the presence of antacids.

Authors:  G Höffken; K Borner; P D Glatzel; P Koeppe; H Lode
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

2.  Study on the bioequivalence of ciprofloxacin 500 mg orally versus 200 mg i.v.

Authors:  R Garraffo; P Lapalus; P Dellamonica; E Bernard; H Etesse
Journal:  Chemioterapia       Date:  1987-06

3.  The comparative pharmacokinetics of five quinolones.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

4.  Ciprofloxacin penetration into lungs.

Authors:  D Honeybourne; R Wise; J M Andrews
Journal:  Lancet       Date:  1987-05-02       Impact factor: 79.321

5.  Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans.

Authors:  J Shimada; T Yamaji; Y Ueda; H Uchida; H Kusajima; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results.

Authors:  P J Hughes; D B Webb; A W Asscher
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

7.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

8.  Pharmacokinetics: metabolism and renal excretion of quinolones in man.

Authors:  T B Vree; W J Wijnands; P J Guelen; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

9.  Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses.

Authors:  T Bergan; S B Thorsteinsson; I M Kolstad; S Johnsen
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

10.  Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora.

Authors:  T Bergan; C Delin; S Johansen; I M Kolstad; C E Nord; S B Thorsteinsson
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

View more
  14 in total

1.  Residues of fluoroquinolones in marine aquaculture environment of the Pearl River Delta, South China.

Authors:  Xiuting He; Zhaohui Wang; Xiangping Nie; Yufen Yang; Debo Pan; Anna O W Leung; Zhang Cheng; Yongtao Yang; Kaibin Li; Kunci Chen
Journal:  Environ Geochem Health       Date:  2011-09-01       Impact factor: 4.609

2.  Ecotoxicological effects of ciprofloxacin on freshwater species: data integration and derivation of toxicity thresholds for risk assessment.

Authors:  N Martins; R Pereira; N Abrantes; J Pereira; F Gonçalves; C R Marques
Journal:  Ecotoxicology       Date:  2012-02-29       Impact factor: 2.823

3.  Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection.

Authors:  Kevin Meesters; Robin Michelet; Reiner Mauel; Ann Raes; Jan Van Bocxlaer; Johan Vande Walle; An Vermeulen
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections.

Authors:  Jasmin Chen; Fang-Yi Su; Debobrato Das; Selvi Srinivasan; Hye-Nam Son; Brian Lee; Frank Radella; Dale Whittington; Taylor Monroe-Jones; T Eoin West; Anthony J Convertine; Shawn J Skerrett; Patrick S Stayton; Daniel M Ratner
Journal:  Biomaterials       Date:  2018-10-16       Impact factor: 12.479

Review 5.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 6.  Quinolones in the elderly.

Authors:  T Bergan
Journal:  Drugs       Date:  1995       Impact factor: 9.546

7.  Absorption of ciprofloxacin in patients with diabetic gastroparesis.

Authors:  M N Marangos; A T Skoutelis; C H Nightingale; Z Zhu; A G Psyrogiannis; D P Nicolau; H P Bassaris; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

8.  Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children.

Authors:  H Peltola; M Väärälä; O V Renkonen; P J Neuvonen
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Transintestinal elimination of ciprofloxacin in humans--concomitant assessment of its metabolites in serum, ileum and colon.

Authors:  B Viell; B Krause; K H Vestweber; S Schaaf; H Scholl
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.